WeVote
Log In

Bill

Bill

S 446

Requires health benefits plans to cover abuse-deterrent opioid analgesic drug products.

2026-2027 Regular Session

New Jersey bill mandates health insurance coverage of abuse-deterrent opioids without cost barriers to reduce misuse potential.

Introduced in the Senate, Referred to Senate Commerce Committee
0
WeVote Research Nonpartisan
Bill Summary · S 446

Legislative bill overview

S 446 requires health insurance plans in New Jersey to cover abuse-deterrent opioid formulations without cost-sharing barriers (such as prior authorization or higher copays). The bill aims to incentivize prescribers and patients to use opioid medications with built-in safeguards against misuse, rather than conventional opioid formulations.

Why is this important

The opioid crisis has driven interest in pharmaceutical innovations designed to reduce abuse potential. By mandating insurance coverage of these formulations, the bill could reduce barriers to access for patients with legitimate pain management needs while theoretically discouraging misuse. However, abuse-deterrent formulations are typically more expensive than conventional opioids, raising questions about healthcare costs and insurance premium impacts.

Potential points of contention

  • Cost implications: Abuse-deterrent opioids are significantly more expensive; insurers and employers may resist mandates that increase premiums without proven population-level benefit
  • Clinical evidence gaps: Limited robust evidence exists that abuse-deterrent formulations meaningfully reduce opioid-related harms at a population level or prevent all forms of misuse
  • Prior authorization debate: The bill restricts insurers' ability to use prior authorization for these drugs, potentially limiting their cost-management tools and raising questions about appropriate prescribing oversight
  • Equitable access concerns: Requirements could benefit patients with good insurance coverage while leaving uninsured/underinsured populations behind

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.